"License to kill" reflects joint action of CD4 and CD8 T cells

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4295-4296

  Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD40 LIGAND; FAS ANTIGEN; GAMMA INTERFERON; GRANZYME B; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; KINESIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; PROTEIN KIF20A; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL AGING; CELL FUNCTION; CELL KILLING; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; HUMAN; IMMUNOMODULATION; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; KINESIN; MALE; NEOPLASMS; PEPTIDES;

EID: 84882999952     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1432     Document Type: Article

References (12)

1. Tomita Y, Akira Y, Tsukamoto H, Senju S, Kroda Y, Hrayama M, et al. Identification of promiscuous KIF20A long peptides bearing both CD4+and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res. 2013;19: 4508-20.
2. Arens R, Schoenberger SP, Plasticity in programming of effector and memory CD8 T cell formation. Immunol Rev 2010;235: 190-205.
3. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010;70:8368-77.
4. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
5. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035-43.
6. Braumuller H, Wieder T, Breuner E, Assman S, Hahn M, Alkhaled M, et al. T helper cell cytokines drive cancer into senescence. Nature 2013;494:361-5.
7. Schuurhuis DH, Laban S, Toes REM, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EIH, et al. Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or-dependent stimuli. J Exp Med 2000;192:145-50.
8. Arens R, van Hall Th, van der Burg SH, Ossendorp F, Melief CJM. Prospects of combinatorial synthetic peptide vaccine-based immu-notherapy. Semin Immunol 2013;pii:S1044-5323(13)00024-9.
9. Speiser D, Romero P. Molecularly defined vaccines for cancer immu-notherapy and protective T cell immunity. Semin Immunol 2010;22: 144-54.
10. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C. Multipeptide immune response to cancer vaccine IMA901 after single dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61.
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDer-mott DF, et al. Safety, activity and immune correlates of anti-OPD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.